Funding Primarily with Internally Generated Funds and Maintaining Sufficient Liquidity
First written in FY2016. 23 of 24 entries say "Restated". Latest entry: FY2026-H1.
103 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「With respect to liquidity, the Company has secured sufficient liquid assets to meet foreseeable working capital requirements.」
The Company has reiterated its policy of relying primarily on internal resources and maintaining sufficient liquid assets to meet foreseeable future funding needs. Cash and cash equivalents amounted to ¥25.771 billion, an increase of ¥958 million from the end of the previous consolidated fiscal year. - FY2025-H1RestatedAnnual report
「With respect to liquidity, the Company has secured sufficient liquid assets to meet foreseeable working capital requirements.」
The Company has reiterated its policy of maintaining sufficient liquid assets to meet foreseeable future funding needs. Cash and cash equivalents amounted to ¥28.410 billion. - FY2024-Q3RestatedAnnual report
「With respect to liquidity, the Company has secured sufficient liquid assets to meet foreseeable working capital requirements. Against this funding base, the Group will seek strategic investment opportunities in overseas markets such as China, the United States and India, while strengthening its research and development capabilities, to enhance the competitiveness of its pharmaceutical business, achieve further growth in overseas markets, develop next-generation technologies and bring new products to market early, and pursue new markets and fields.」
The Company has reiterated its policy of maintaining sufficient liquid assets and using internal resources to fund investment in research and development and overseas markets. - FY2024-Q2RestatedAnnual report
「With respect to liquidity, the Company has secured sufficient liquid assets to meet foreseeable working capital requirements.」
The Company has reiterated its policy of maintaining sufficient liquid assets to meet foreseeable future funding needs and funding business operations and investments primarily with internal resources. Cash and cash equivalents amounted to ¥22.040 billion. - FY2023RestatedAnnual report
「With respect to liquidity, the Company has secured sufficient liquid assets to meet foreseeable working capital requirements.」
The Company has reiterated its policy of maintaining sufficient liquid assets and funding business operations and investments primarily with internal resources. Cash and cash equivalents at the end of the fiscal year amounted to ¥21.997 billion. - FY2023-Q2RestatedAnnual report
「With respect to liquidity, the Company has secured sufficient liquid assets to meet foreseeable working capital requirements.」
The Company has reiterated its policy of maintaining sufficient liquid assets, funding business operations and investments primarily with internal resources, and preparing for additional funding needs in the future. Cash and cash equivalents at the end of the fiscal year amounted to ¥20.541 billion. - FY2022RestatedAnnual report
「With respect to liquidity, the Company has secured sufficient liquid assets to meet foreseeable working capital requirements.」
The Company has reiterated its policy of maintaining sufficient liquidity, relying primarily on internal resources, and pursuing research and development and investment in overseas markets. Cash and cash equivalents at the end of the fiscal year amounted to ¥16.845 billion. - FY2022-Q3RestatedAnnual report
「With respect to liquidity, the Company has secured sufficient liquid assets to meet foreseeable working capital requirements.」
The Company has reiterated its policy of maintaining sufficient liquid assets to meet foreseeable future funding needs. - FY2021-Q3RestatedAnnual report
「With respect to liquidity, the Company has secured sufficient liquid assets to meet foreseeable working capital requirements. Against this funding base, the Group will seek strategic investment opportunities in overseas markets such as China, the United States, Europe and India, while strengthening its research and development capabilities, to enhance the competitiveness of its pharmaceutical business, achieve further growth in overseas markets, develop next-generation technologies and bring them to market early, and pursue new markets and fields.」
The Company has reiterated its policy of maintaining sufficient liquid assets and using internal resources to pursue research and development, investment in overseas markets, next-generation technology development, and initiatives in new markets and fields. - FY2020-Q3RestatedAnnual report
「Although we believe that business development should preferably be funded with internal resources, we will continuously strive to maintain a sound financial base so that, if funding needs exceeding those resources arise in the future, we can raise the necessary funds smoothly and at low cost.」
The Company has reiterated its policy of relying primarily on internal resources while maintaining a sound financial base in preparation for additional funding needs in the future. - FY2020-Q2RestatedAnnual report
「With respect to liquidity, the Company has secured sufficient liquid assets to meet foreseeable working capital requirements. Against this funding base, the Group will seek strategic investment opportunities in overseas markets such as China, the United States, Europe and India, while strengthening its research and development capabilities, to enhance the competitiveness of its pharmaceutical business, achieve further growth in overseas markets, develop next-generation technologies and bring them to market early, and pursue new markets and fields.」
The Company has reiterated its policy of maintaining sufficient liquid assets and using its financial base to fund investment in research and development and overseas markets. - FY2020-Q1RestatedAnnual report
「With respect to liquidity, the Company has secured sufficient liquid assets to meet foreseeable working capital requirements. Against this funding base, the Group will seek strategic investment opportunities in overseas markets such as China, the United States, Europe and India, while strengthening its research and development capabilities, to enhance the competitiveness of its pharmaceutical business, achieve further growth in overseas markets, develop next-generation technologies and bring them to market early, and pursue new markets and fields.」
The Company has reiterated its policy of maintaining sufficient liquid assets and using internal resources to fund investment in research and development and overseas markets. - FY2019RestatedAnnual report
「With respect to liquidity, the Company has secured sufficient liquid assets to meet foreseeable working capital requirements.」
The Company has reiterated its policy of maintaining sufficient liquid assets and pursuing business investment while maintaining its financial base. - FY2019-Q3RestatedAnnual report
「With respect to liquidity, the Company has secured sufficient liquid assets to meet foreseeable working capital requirements. Against this funding base, the Group will seek strategic investment opportunities in overseas markets such as China, the United States, Europe and India, while strengthening its research and development capabilities, to enhance the competitiveness of its pharmaceutical business, achieve further growth in overseas markets, develop next-generation technologies and bring them to market early, and pursue new markets and fields.」
The Company has reiterated its policy of maintaining sufficient liquid assets and using internal resources to fund investment in research and development and overseas markets. - FY2019-Q2RestatedAnnual report
「With respect to liquidity, the Company has secured sufficient liquid assets to meet foreseeable working capital requirements.」
The Company has reiterated its policy of maintaining sufficient liquid assets and funding business operations and investments primarily with internal resources. - FY2019-Q1RestatedAnnual report
「With respect to liquidity, the Company has secured sufficient liquid assets to meet foreseeable working capital requirements.」
The Company has reiterated its policy of maintaining sufficient liquid assets and funding business operations and investments primarily with internal resources. - FY2018RestatedAnnual report
「With respect to liquidity, the Company has secured sufficient liquid assets to meet foreseeable working capital requirements.」
The Company has reaffirmed its policy of maintaining sufficient cash liquidity and funding business investments and working capital primarily with internal resources. - FY2018-Q2RestatedAnnual report
「The Company plans to meet these funding needs primarily with internal resources, consisting of cash on hand and funds generated from operating activities. As funding facilities, it has entered into an overdraft agreement with its principal financial institutions with a borrowing limit of ¥1.8 billion and a master agreement for the sale and purchase of bills receivable with a sales limit of ¥600 million. The Company also plans to obtain long-term borrowings as necessary to ensure smooth and efficient funding.」
The Company has reiterated its policy of relying primarily on internal resources, supplemented by overdrafts, sales and purchase of bills receivable and long-term borrowings as necessary. Cash and cash equivalents amounted to ¥11.054 billion, and time deposits amounted to ¥932 million. - FY2018-Q1RestatedAnnual report
「Cash and cash equivalents at the end of the first quarter of the current fiscal year amounted to ¥8.808 billion, providing sufficient working capital for foreseeable funding needs. In addition, although not included in cash and cash equivalents, the Company held ¥1.102 billion in time deposits that could readily be converted into cash, ensuring sufficient liquid assets.」
The Company disclosed its policy of relying primarily on internal resources for funding, along with sufficient liquidity comprising ¥8.808 billion in cash and ¥1.102 billion in time deposits. - FY2018-Q1RestatedAnnual report
「The Company plans to meet these funding needs primarily with internal resources, consisting of cash on hand and funds generated from operating activities. As funding facilities, it has entered into an overdraft agreement with its principal financial institutions with a borrowing limit of ¥1.8 billion and a master agreement for the sale and purchase of bills receivable with a sales limit of ¥600 million. The Company also plans to obtain long-term borrowings as necessary to ensure smooth and efficient funding.」
The Company has reiterated its funding policy of relying primarily on internal resources, supplemented by overdrafts, agreements for the sale and purchase of bills receivable and long-term borrowings as necessary. - FY2017RestatedAnnual report
「The Company plans to meet these funding needs primarily with internal resources, consisting of cash on hand and funds generated from operating activities. As funding facilities, it has entered into an overdraft agreement with its principal financial institutions with a borrowing limit of ¥1.8 billion and a master agreement for the sale and purchase of bills receivable with a sales limit of ¥600 million. The Company also plans to obtain long-term borrowings as necessary to ensure smooth and efficient funding.」
The Company has reiterated its policy of meeting funding needs primarily with internal resources, supplemented by overdraft facilities, agreements for the sale and purchase of bills receivable and long-term borrowings as necessary. - FY2017-Q3RestatedAnnual report
「The Company plans to meet these funding needs primarily with internal resources, consisting of cash on hand and funds generated from operating activities.」
The Company has reiterated its policy of funding working capital, investments for business expansion and dividends primarily with internal resources, supplemented by overdraft facilities and other means. - FY2017-Q1RestatedAnnual report
「The Company plans to meet these funding needs primarily with internal resources, consisting of cash on hand and funds generated from operating activities.」
The Company has reiterated its policy of funding working capital, investments for business expansion and dividends primarily with internal resources. - FY2016First statedAnnual report
「The Company plans to meet these funding needs primarily with internal resources, consisting of cash on hand and funds generated from operating activities.」
The policy is to fund working capital, investments and dividends primarily with internal resources, supplemented by borrowing facilities and other means.